このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Protagonist Therapeutics 将来の成長
Future 基準チェック /06
Protagonist Therapeuticsの収益と利益はそれぞれ年間4.1%と1.7%減少すると予測されていますが、EPS は年間5.7% 減少すると予測されています。
主要情報
-1.7%
収益成長率
-5.7%
EPS成長率
| Biotechs 収益成長 | 24.5% |
| 収益成長率 | -4.1% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 14 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 146 | -51 | -108 | N/A | 3 |
| 12/31/2025 | 94 | -34 | -113 | -62 | 5 |
| 12/31/2024 | 292 | 103 | 197 | 285 | 6 |
| 3/31/2024 | 315 | 162 | -64 | -63 | N/A |
| 12/31/2023 | 60 | -79 | -71 | -70 | N/A |
| 9/30/2023 | N/A | -140 | -119 | -119 | N/A |
| 6/30/2023 | N/A | -138 | -118 | -117 | N/A |
| 3/31/2023 | 1 | -140 | -105 | -105 | N/A |
| 12/31/2022 | 27 | -127 | -109 | -108 | N/A |
| 9/30/2022 | 35 | -130 | -104 | -103 | N/A |
| 6/30/2022 | 45 | -133 | -108 | -107 | N/A |
| 3/31/2022 | 47 | -122 | -118 | -117 | N/A |
| 12/31/2021 | 27 | -126 | -109 | -108 | N/A |
| 9/30/2021 | 24 | -108 | -101 | -100 | N/A |
| 6/30/2021 | 27 | -81 | -88 | -88 | N/A |
| 3/31/2021 | 31 | -70 | -86 | -85 | N/A |
| 12/31/2020 | 29 | -66 | -73 | -72 | N/A |
| 9/30/2020 | 26 | -65 | -68 | -68 | N/A |
| 6/30/2020 | 17 | -73 | -66 | -66 | N/A |
| 3/31/2020 | 2 | -83 | -42 | -41 | N/A |
| 12/31/2019 | 0 | -77 | -42 | -42 | N/A |
| 9/30/2019 | 0 | -74 | -38 | -37 | N/A |
| 6/30/2019 | 2 | -66 | -34 | -32 | N/A |
| 3/31/2019 | 22 | -45 | -52 | -51 | N/A |
| 12/31/2018 | 31 | -39 | -50 | -50 | N/A |
| 9/30/2018 | 40 | -28 | -54 | -54 | N/A |
| 6/30/2018 | 43 | -24 | -5 | -4 | N/A |
| 3/31/2018 | 31 | -31 | -2 | -1 | N/A |
| 12/31/2017 | 20 | -37 | N/A | 4 | N/A |
| 9/30/2017 | 9 | -45 | N/A | 8 | N/A |
| 6/30/2017 | N/A | -48 | N/A | -39 | N/A |
| 3/31/2017 | N/A | -40 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -38 | N/A | -30 | N/A |
| 9/30/2016 | N/A | -32 | N/A | -25 | N/A |
| 6/30/2016 | N/A | -28 | N/A | -22 | N/A |
| 3/31/2016 | N/A | -24 | N/A | -17 | N/A |
| 12/31/2015 | N/A | -15 | N/A | -14 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PTGXの収益は今後 3 年間で減少すると予測されています (年間-1.7% )。
収益対市場: PTGXの収益は今後 3 年間で減少すると予測されています (年間-1.7% )。
高成長収益: PTGXの収益は今後 3 年間で減少すると予測されています。
収益対市場: PTGXの収益は今後 3 年間で減少すると予想されています (年間-4.1% )。
高い収益成長: PTGXの収益は今後 3 年間で減少すると予測されています (年間-4.1% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PTGXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です